Featured Research

from universities, journals, and other organizations

Cancer support drug may help critically injured kids fight off deadly infections

Date:
June 3, 2014
Source:
Ohio State University Center for Clinical and Translational Science
Summary:
Traumatic injury is the number one cause of death in children above the age of one. Not only are injuries often life-threatening, but the severity of the injuries can “paralyze” the immune system, increasing a child’s risk for developing potentially deadly secondary infections. Researchers are now testing a drug commonly used to boost the immune systems of kids with cancer to see if it can also help children with life-threatening injuries avoid infection.

When 8-year old Tiffany was rushed into the emergency room at Nationwide Children's Hospital, she was suffering from multiple fractures and internal bleeding after being in a horrific car accident. Physicians were able to stabilize her, and within a few hours, she was on a ventilator in the intensive care unit. Here, she began a second fight for her life -- battling nosocomial or hospital acquired infections, which nationally, affect as many as 40 percent of critically injured kids in the ICU.

"Sometimes, injuries are so severe that the innate immune system becomes deeply impaired and unable to respond to normally to infection," said Mark Hall, MD, a Critical Care Medicine physician and scientist at the Center for Clinical and Translational Research at Nationwide Children's (NCH). "These secondary infections represent serious complications, can result in extended hospital stays and, in very rare instances, death."

Usually, Tiffany would simply be observed for signs of infection while she was in the ICU. But as part of a clinical trial led by Hall, she is one of the first kids in the country to receive a drug called GM-CSF that researchers hope will boost her immune system enough so that it can fight off potential infections.

GM-CSF has been used for more than 20 years to help restore the immune systems of pediatric cancer patients after they have undergone chemotherapy or received a bone marrow transplant. GM-CSF helps improve the function of existing immune system cells and prompts the bone marrow to make new cells, which can help normalize the immune response. Researchers think just a fraction of the dose of GM-CSF usually used in cancer patients may also help reset an immune system disrupted by extreme trauma.

"In the aftermath of a critical injury we sometimes see a strong inflammatory immune response followed by an overactive anti-inflammatory response which in effect, paralyzes the immune system," noted Hall. "By using a simple blood test, within hours we know which kids with trauma are in this immunoparalyzed state, and who may benefit from GM-CSF."

Tiffany's blood was put through a panel of tests in Hall's Immune Surveillance Laboratory, designed specifically to look at several parameters in immune response. "We basically take a chemical stick and poke the blood cells to see if they react the way they should, and that gives us a window into the strength of a child's immune system, " said Hall.

The "stick" is designed to induce the production of TNFα, a key immune response chemical. Hall conducted several earlier observational studies that helped establish a TNFα production threshold that is associated with infection risk; if the TNFα response is below this threshold, the child's risk for developing a secondary infection or dying increases.

Tiffany was enrolled in the GIFT (GM-CSF for Immunomodulation Following Trauma) study, and every day, for the first three days Tiffany was in the ICU, Hall's team tested her immune function. They found she was producing very low quantities of TNFα, so she was given GM-CSF. Tiffany's immune system bounced back. She made a full -- and infection-free- recovery in the ICU.

Funded by a 5-year grant from the National Institute of General Medical Sciences and supported by the Ohio State Center for Clinical and Translational Science (CCTS), the GIFT study is in the first of two phases, where researchers are determining the lowest tolerable, yet effective dose. Within one year, researchers will begin the efficacy phase, where critically injured children will be randomized to receive either GM-CSF or placebo.

Hall says that the team is also stratifying the study group based on pubertal status, hypothesizing that sex hormones may alter the dose-response, and by children who have severe traumatic brain injury (TBI), noting that neurohormonal influences affect immune function after severe TBI.

Hall is also optimistic that his approach to same-day immune function monitoring will become a standard part of lab tests performed on kids with life-threatening injuries so that they can receive targeted, patient-specific immune system support.

"We're hoping that within the next five to ten years, our findings will help establish a new standard of care for children whose immune systems have been impaired by life-threatening injuries," said Hall. "Plus, what we've learned about the trauma related immune response could be applied to other critical conditions like sepsis or influenza where kids are particularly vulnerable."


Story Source:

The above story is based on materials provided by Ohio State University Center for Clinical and Translational Science. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University Center for Clinical and Translational Science. "Cancer support drug may help critically injured kids fight off deadly infections." ScienceDaily. ScienceDaily, 3 June 2014. <www.sciencedaily.com/releases/2014/06/140603091956.htm>.
Ohio State University Center for Clinical and Translational Science. (2014, June 3). Cancer support drug may help critically injured kids fight off deadly infections. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/06/140603091956.htm
Ohio State University Center for Clinical and Translational Science. "Cancer support drug may help critically injured kids fight off deadly infections." ScienceDaily. www.sciencedaily.com/releases/2014/06/140603091956.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins